--- name: diligence-scorecard description: > Generate a comprehensive 8-pillar investment diligence scorecard for a therapeutic asset or biotech company by synthesizing clinical, regulatory, competitive, manufacturing, IP, financial, team, and computational infrastructure assessments into a structured scoring framework with an investment recommendation. Activate when producing a complete diligence deliverable or synthesizing all prior analyses into a single decision framework. metadata: author: nirav version: "1.0" innovation: "8th pillar (Computational Infrastructure) reflects $1B+ AI science factory mega-rounds" compatibility: Designed for Claude Code allowed-tools: Read, WebSearch, WebFetch --- # Diligence Scorecard — The Integration Engine This is the capstone skill of the Asclepius domain. Every other skill produces a component analysis; the diligence scorecard synthesizes all of them into the artifact that venture investors actually produce — a structured, scored assessment with an explicit recommendation. No open-source biotech diligence scorecard exists. The 8-pillar framework is deliberately opinionated. Seven pillars are standard in biotech diligence. The 8th — Computational Infrastructure — reflects the $1B+ mega-rounds flowing to AI science factories (Xaira $1B, Isomorphic $600M, Lila Sciences $350M) and the growing requirement that founding teams have computational expertise (Dimension Capital). This is where your Formation Bio experience creates maximum differentiation. ## How to Run ### Input The scorecard consumes outputs from all other Asclepius skills: | Input Source | Pillar(s) Fed | |---|---| | pos-calculator | Pillar 1 (Clinical Strength) | | endpoint-selection | Pillar 1, Pillar 2 | | trial-design-optimizer | Pillar 1 | | regulatory-precedent + pathway-analyzer | Pillar 2 (Regulatory Positioning) | | regulatory-risk-scorer | Pillar 2 | | clinical-differentiator + pipeline-mapper | Pillar 3 (Competitive Position) | | market-dynamics | Pillar 3 | | cmc-risk-assessor + modality-manufacturing | Pillar 4 (Manufacturing Feasibility) | | patent-analyzer + ip-valuation | Pillar 5 (IP Fortress) | | rnpv-modeler + peak-sales-forecaster + deal-economics | Pillar 6 (Financial Attractiveness) | | User assessment / public information | Pillar 7 (Team & Execution) | | User assessment / public information | Pillar 8 (Computational Infrastructure) | If upstream analyses haven't been run, the scorecard can operate with partial information — but must flag which pillars are scored on limited data. ### Steps #### Step 1 — Score Each Pillar (1-10) Use the scoring calibration in `references/scoring-calibration.md` for criteria at each level. **Pillar 1: Clinical Strength (Weight: 20%)** Assess: PoS from pos-calculator, endpoint quality from endpoint-selection, data maturity, biomarker strategy. Key question: "Is the clinical evidence compelling enough to justify Phase 3 investment?" **Pillar 2: Regulatory Positioning (Weight: 15%)** Assess: Pathway from pathway-analyzer, regulatory risk from regulatory-risk-scorer, designation status, precedent depth. Key question: "Does the regulatory path to approval have precedent and manageable risk?" **Pillar 3: Competitive Position (Weight: 15%)** Assess: Differentiation from clinical-differentiator, landscape from pipeline-mapper, market dynamics. Key question: "Can this asset win meaningful market share against current and future competitors?" **Pillar 4: Manufacturing Feasibility (Weight: 10%)** Assess: CMC risk from cmc-risk-assessor, COGS from modality-manufacturing, scalability. Key question: "Can this drug be manufactured reliably at commercial scale at acceptable COGS?" **Pillar 5: IP Fortress (Weight: 10%)** Assess: Patent landscape from patent-analyzer, IP contribution from ip-valuation, exclusivity periods. Key question: "Is the IP strong enough to protect commercial returns through peak sales?" **Pillar 6: Financial Attractiveness (Weight: 15%)** Assess: rNPV from rnpv-modeler, peak sales from peak-sales-forecaster, deal terms from deal-economics. Key question: "Does the risk-adjusted return justify the capital at risk?" **Pillar 7: Team & Execution (Weight: 10%)** Assess: Management experience, board composition, operational capability, capital adequacy. Key question: "Can this team execute the development plan and navigate setbacks?" **Pillar 8: Computational Infrastructure (Weight: 5%)** Assess: AI/ML platform maturity, proprietary data assets, wet-lab/dry-lab integration, computational team depth. Key question: "Does this company have computational capabilities that accelerate development or create data moats?" #### Step 2 — Check for Red Flags Red flags automatically cap the aggregate score at 4.0: - Going concern risk (<6 months cash, no financing path) - Data integrity concerns - Regulatory rejection (CRL) without clear resubmission path - Core patent invalidated - Management exodus (CEO + CSO departed) #### Step 3 — Check for Green Flags Green flags add +0.5 to aggregate (cap at 10.0): - Significant insider buying (>$500K open market) - Top-tier VC validation (Arch, Flagship, Third Rock) - Big pharma co-development partnership - Platform with multiple advancing indications #### Step 4 — Calculate Aggregate Score ``` Aggregate = Σ (Pillar Score × Weight) + Green Flag Bonus - Red Flag Cap ``` #### Step 5 — Generate Recommendation | Aggregate | Recommendation | Position Sizing | |---|---|---| | 8.0-10.0 | **Strong Buy** | Maximum position (3-5% of fund) | | 6.5-7.9 | **Buy** | Standard position (1-3% of fund) | | 5.0-6.4 | **Hold** | Monitor for catalysts; small position if specific thesis | | 3.5-4.9 | **Cautious** | Below average; avoid unless compelling contrarian thesis | | 1.0-3.4 | **Avoid** | Fundamental concerns; do not invest | ### Output ``` DILIGENCE SCORECARD — [Company / Asset Name] Indication: [therapeutic area + indication] Current Phase: [development stage] Date: [assessment date] Analyst: [name] ═══════════════════════════════════════════════ PILLAR SCORES Score Weight Weighted 1. Clinical Strength [X/10] 20% [X.X] 2. Regulatory Positioning [X/10] 15% [X.X] 3. Competitive Position [X/10] 15% [X.X] 4. Manufacturing Feasibility [X/10] 10% [X.X] 5. IP Fortress [X/10] 10% [X.X] 6. Financial Attractiveness [X/10] 15% [X.X] 7. Team & Execution [X/10] 10% [X.X] 8. Computational Infrastructure [X/10] 5% [X.X] ───────────────────── AGGREGATE: [X.X / 10.0] Red Flags: [None / List] Green Flags: [None / List] Adjusted Aggregate: [X.X / 10.0] ═══════════════════════════════════════════════ RECOMMENDATION: [Strong Buy / Buy / Hold / Cautious / Avoid] One-Line Thesis: [Single sentence investment thesis] Key Catalysts: 1. [Catalyst + expected date + value impact] 2. [Catalyst + expected date + value impact] 3. [Catalyst + expected date + value impact] Key Risks: 1. [Risk + probability + impact + mitigant] 2. [Risk + probability + impact + mitigant] 3. [Risk + probability + impact + mitigant] Financial Summary: rNPV: $[X]M (range: $[low] - $[high]) Peak Sales: $[X]B PoS (LOA): [X]% Next Value Inflection: [event] ([X]x potential) Pillar-Level Detail: Strongest Pillar: [name] ([score]) — [why] Weakest Pillar: [name] ([score]) — [why, and what would improve it] ═══════════════════════════════════════════════ DATA COMPLETENESS Pillars with full upstream analysis: [list] Pillars scored on limited data: [list + what's missing] Confidence in aggregate: [High / Medium / Low] ``` ## Error Handling | Scenario | Response | |---|---| | Missing upstream analysis for a pillar | Score based on available information; flag as "limited data" in output; widen confidence range | | Private company (limited public data) | Pillars 7-8 may rely on investor deck + news; note data source limitations | | Pre-clinical company | Pillars 1, 2, 3 scored conservatively; emphasize platform/team over clinical data | | Multi-asset company | Score lead asset as primary; note pipeline optionality as green flag | | User disagrees with a pillar score | Pillar weights are configurable; user can adjust weight to 0% to exclude a pillar | ## Cross-Domain Connections - **All biotech-venture skills**: This is the integration point — every other skill feeds into at least one pillar - **Biotech-venture/investment-memo-writer**: Scorecard outputs feed directly into IC memo generation - **Biotech-venture/portfolio-analyzer**: Individual scorecards feed portfolio-level analysis - **Investing/archon**: Scorecard parallels Archon's investment thesis evaluation framework - **Investing/second-level-thinking**: Red/green flag analysis applies contrarian lens